Director, Oncology Translational Medicine
Leads the development and execution of biomarker and translational medicine strategies for late-stage oncology programs, integrating cutting-edge technologies to identify predictive biomarkers and optimise patient selection. Works within cross-functional clinical teams to embed biomarker-driven decision-making into trial design and development plans. Focuses on validating pharmacodynamic, target engagement, and resistance mechanisms to inform clinical go/no-go decisions and life cycle management.